EP3759081A1 - An improved process for the preparation of propiomazine maleate - Google Patents

An improved process for the preparation of propiomazine maleate

Info

Publication number
EP3759081A1
EP3759081A1 EP19760246.9A EP19760246A EP3759081A1 EP 3759081 A1 EP3759081 A1 EP 3759081A1 EP 19760246 A EP19760246 A EP 19760246A EP 3759081 A1 EP3759081 A1 EP 3759081A1
Authority
EP
European Patent Office
Prior art keywords
formula
propiomazine
preparation
maleate
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19760246.9A
Other languages
German (de)
French (fr)
Other versions
EP3759081A4 (en
Inventor
Kannasani RAVI KUMAR
Kasa Mallik Yadav
Mula SREENU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RA Chem Pharma Ltd
Original Assignee
RA Chem Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RA Chem Pharma Ltd filed Critical RA Chem Pharma Ltd
Publication of EP3759081A1 publication Critical patent/EP3759081A1/en
Publication of EP3759081A4 publication Critical patent/EP3759081A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part

Definitions

  • the present invention relates to an improved process for the preparation of Propiomazine maleate. More particularly, the invention relates to a cost-effective process, which provides Propiomazine maleate of formula-I with high purity, which is free from isomeric impurity, specifically isopropiomazine.
  • Propiomazine maleate of formula-I is a phenothiazine derivative, chemically known as 1-[10-(2-dimethylaminopropyl)-10H-phenothiazin-2-yl]propan-1-one maleate.
  • Propiomazine is an antihistamine drug, which acts by blocking H1 receptors. It is used to treat insomnia, and to produce sleepiness or drowsiness and to relieve anxiety before or during surgery or other procedures and in combination with analgesics also during labor. Propiomazine is a derivative of Phenothiazine.
  • the main object of the present invention is to provide simple, cost-effective and industrially viable method for the preparation of Propiomazine maleate of formula-I on commercial scale.
  • the main aspect of the present invention is to provide an improved process for the preparation of Propiomazine maleate of formula-I.
  • the second aspect of the present invention is process for preparation of Propiomazine maleate with high purity which is free from isomeric impurity of formula-III.
  • the isomeric impurity produced during the preparation of Propiomazine base of formula II is controlled during the preparation of Propiomazine maleate.
  • the Propiomazine base of formula II is dissolved in alcoholic media to get a clear solution. Addition of maleic acid to the above clear solution produces Propiomazine maleate of formula-I which is free from isomeric impurity.
  • the present invention relates to an improved process for the preparation of Propiomazine maleate of formula-I and its purification from the undesired isomeric impurity. i.e., isopropiomazine of formula-III.
  • the first embodiment of the present invention is an improved process for the preparation of 1-[10-(2-dimethylaminopropyl)-10H-phenothiazin-2-yl]propan-1-one of formula-II, which comprises condensing 2-propionyl phenothiazine of formula –IV
  • Further embodiment of the present invention relates to process for preparation of Propiomazine maleate with high purity and free from isopropiomazine impurity of formula-III.
  • the isomeric impurity is controlled during the preparation of Propiomazine maleate.
  • the crude Propiomazine base obtained in the above condensation step contains isomeric impurity of 20-25%.
  • the Propiomazine base of formula II is dissolved in alcoholic media to get a clear solution. Addition of maleic acid to the above clear solution produces Propiomazine maleate of formula-I which is free from isomeric impurity.
  • the process is schematically represented as below:
  • the base used in condensation step is selected from potassium hydroxide, sodium hydroxide, potassium tertiary butoxide, preferably potassium hydroxide.
  • solvent used in condensation step is selected from the group comprising of toluene, xylene, preferably toluene.
  • alcoholic media used in purification step is selected from methanol, ethanol, isopropyl alcohol, preferably methanol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an improved process for the preparation of highly pure Propiomazine Maleate of formula-I. More particularly, the invention relates to a cost-effective process, which provides Propiomazine maleate of formula-I with high purity, which is free from isomeric impurity of formula-III, specifically isopropiomazine. The isomeric impurity is controlled during the preparation of Propiomazine maleate. (I)

Description

    AN IMPROVED PROCESS FOR THE PREPARATION OF PROPIOMAZINE MALEATE
  • The present invention relates to an improved process for the preparation of Propiomazine maleate. More particularly, the invention relates to a cost-effective process, which provides Propiomazine maleate of formula-I with high purity, which is free from isomeric impurity, specifically isopropiomazine.
  • [Chem .1]
    •
  • Propiomazine maleate of formula-I is a phenothiazine derivative, chemically known as 1-[10-(2-dimethylaminopropyl)-10H-phenothiazin-2-yl]propan-1-one maleate.
  • [Chem .2]
  • Propiomazine is an antihistamine drug, which acts by blocking H1 receptors. It is used to treat insomnia, and to produce sleepiness or drowsiness and to relieve anxiety before or during surgery or other procedures and in combination with analgesics also during labor. Propiomazine is a derivative of Phenothiazine.
  • The process for preparation of Propiomazine has been discussed in “Kathleen B. Crombie and Leo F. Cullen. Analytical profiles of drug substances., pp 439-466 (1973)” which reported two synthetic routes for the preparation of Propiomazine hydrochloride.
  • According to the above review artic le, one of the two synthetic routes is illustrated in Scheme-1 discloses the preparation of Propiomazine base by reacting 2-dimethylaminopropyl chloride with 2-propionylphenothiazine in the presence of sodium amide as the condensing agent, and subsequently converting the base form to the hydrochloride.
  • [Chem .3]
  • The other synthesis route is illustrated in Scheme-2, which was developed by Establissements Clin-RylaB for the preparation of Propiomazine hydrochloride is based on the decarboxylation by heating of the aminoalkyl ester of the N-carboxyphenothiazine. Specifically 2-propionylphenothiazine is converted in to its N-carbonyl chloride derivative by reacting with phosgene. Reaction of the chloride with 2-dimethylamino-1-propanol yields the ester hydrochloride, which is decarboxylated by heating to obtain Propiomazine hydrochloride.
  • [Chem .4]
  • The above mentioned routes for Propiomazine hydrochloride have considerable disadvantages, which involve multiple steps for the synthesis and use of expensive starting materials.
  • Synthesis of Propiomazine maleate has not been disclosed in any literature which is available in the public domain.
  • The present inventors have now found a simple, cost-effective process, which provides propiomazine maleate with high purity and free from isopropiomazine impurity.
    Object of the Invention
  • The main object of the present invention is to provide simple, cost-effective and industrially viable method for the preparation of Propiomazine maleate of formula-I on commercial scale.
    •
  • The main aspect of the present invention is to provide an improved process for the preparation of Propiomazine maleate of formula-I.
  • [Chem .5]
  • The first aspect of the present invention is to provide an improved process for the preparation of 1-[10-(2-dimethylaminopropyl)-10H-phenothiazin-2-yl]propan-1-one of formula-II comprises the steps of reacting hydrochloride salt of 2-dimethylaminoisopropyl chloride with 2-propionyl phenothiazine in presence of a base and suitable solvent which is selected from the group comprising of toluene, xylene, preferably toluene.
  • [Chem .6]
  • The second aspect of the present invention is process for preparation of Propiomazine maleate with high purity which is free from isomeric impurity of formula-III. The isomeric impurity produced during the preparation of Propiomazine base of formula II is controlled during the preparation of Propiomazine maleate. The Propiomazine base of formula II is dissolved in alcoholic media to get a clear solution. Addition of maleic acid to the above clear solution produces Propiomazine maleate of formula-I which is free from isomeric impurity.
  • [Chem .7]
    •
  • The present invention relates to an improved process for the preparation of Propiomazine maleate of formula-I and its purification from the undesired isomeric impurity. i.e., isopropiomazine of formula-III.
  • The first embodiment of the present invention is an improved process for the preparation of 1-[10-(2-dimethylaminopropyl)-10H-phenothiazin-2-yl]propan-1-one of formula-II, which comprises condensing 2-propionyl phenothiazine of formula –IV

  • with hydrochloride salt of 2-dimethylaminoisopropyl chloride of formula-V
  • [Chem .9]

    in presence of a base and suitable solvent to obtain the compound of Propiomazine base of formula-II.
    The process is schematically represented as below:
  • [Chem .10]
  • Further embodiment of the present invention relates to process for preparation of Propiomazine maleate with high purity and free from isopropiomazine impurity of formula-III. The isomeric impurity is controlled during the preparation of Propiomazine maleate. The crude Propiomazine base obtained in the above condensation step contains isomeric impurity of 20-25%. The Propiomazine base of formula II is dissolved in alcoholic media to get a clear solution. Addition of maleic acid to the above clear solution produces Propiomazine maleate of formula-I which is free from isomeric impurity.
    The process is schematically represented as below:
  • [Chem .11]

    According to one embodiment of the present invention the base used in condensation step is selected from potassium hydroxide, sodium hydroxide, potassium tertiary butoxide, preferably potassium hydroxide.
    According to another embodiment of the present invention solvent used in condensation step is selected from the group comprising of toluene, xylene, preferably toluene.
    According to yet another embodiment of the present invention alcoholic media used in purification step is selected from methanol, ethanol, isopropyl alcohol, preferably methanol.
    The present invention can be illustrated in the following non- limiting example.
  • Examples
  • Preparation of Propiomazine maleate: To a stirred solution of 2-dimethylaminoisopropyl chloride hydrochloride (67.5 gm, 0.427 mole) in water (50 ml) and Toluene (250 ml) mixture was basified with aqueous sodium hydroxide solution at below 10oC and separate the organic layer. To obtained base toluene layer was added 2-propionyl phenothiazine (50 gm, 0.171 mole) and potassium hydroxide flakes (19 gm, 0.342 mole) at below 10oC. Reaction mixture temperature was slowly heated to reflux and maintained for 5-6 hrs under azeotropic condition. Progress of the reaction was monitored/ confirmed by HPLC. After completion of reaction, the reaction mixture was cooled to 25-30oC and water (200 ml) was added and stirred for 10-15 minutes. The organic layer was separated and concentrated to get Propiomazine crude compound. Crude compound was dissolved in methanol (200 ml) and stirred for 10-15 minutes at 25-30oC to get clear solution, Maleic acid (20 gm) was added to the above clear solution and stirring was continued for another 4-5 hrs at 25-30oC and the precipitated solid was filtered and dried to get Propiomazine maleate in pure form. Yield: 34 gms.
    Purity: greater than 99.5% and isopropiomazine content below 0.10% by HPLC.
    •

Claims (9)

  1. An improved process for the preparation of Propiomazine of formula-II, comprising condensing 2-propionyl phenothiazine of formula –IV.

    with hydrochloride salt of 2-dimethylaminoisopropyl chloride of formula-V

    in presence of a base and suitable solvent to obtain the compound of Propiomazine of formula II.
  2. Process for the preparation of Propiomazine Maleate of formula-I, comprising condensing 2-propionyl phenothiazine of formula –IV

    with hydrochloride salt of 2-dimethylaminoisopropyl chloride of formula-V

    in presence of a base and suitable solvent to obtain the compound of Propiomazine
    of formula II.

    which is further dissolved in alcoholic media to get clear solution and added maleic acid to obtain the compound of Propiomazine maleate of formula-I,

    which is free from isomeric impurity of formula-III.
  3. An improved process for the preparation of Propiomazine of formula-II, comprising condensing 2-propionyl phenothiazine of formula –IV

    with hydrochloride salt of 2-dimethylaminoisopropyl chloride of formula-V

    in presence of a base and toulene to obtain the compound of Propiomazine of formula II.
  4. An improved process for the preparation of Propiomazine of formula-II, comprising condensing 2-propionyl phenothiazine of formula –IV

    with hydrochloride salt of 2-dimethylaminoisopropyl chloride of formula-V

    in presence of a potassium hydroxide and suitable solvent to obtain the compound of Propiomazine of formula II.
  5. The process claimed in claim 1, 2 and 3 base is selected from group comprising of Potassium hydroxide, sodium hydroxide, potassium tertiary butoxide.
  6. The process claimed in claim 1, 2 and 4 solvent is selected from the group comprising of Toluene, xylene.
  7. The process for the preparation of Propiomazine maleate, comprising Propiomazine base of formula II is dissolved in alcoholic media to get a clear solution and added maleic acid to obtain the compound of Propiomazine maleate of formula I, which is free from isomeric impurity of formula-III.

  8. Propiomazine maleate having purity of greater than 99.5% wherein the isomeric impurity of formula III is below 0.10% by HPLC.
  9. The process claimed in claim 7, alcoholic media is selected from the group comprising methanol, ethanol, isopropyl alcohol preferably methanol.
EP19760246.9A 2018-02-27 2019-02-18 An improved process for the preparation of propiomazine maleate Pending EP3759081A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841007386 2018-02-27
PCT/IN2019/050128 WO2019167058A1 (en) 2018-02-27 2019-02-18 An improved process for the preparation of propiomazine maleate

Publications (2)

Publication Number Publication Date
EP3759081A1 true EP3759081A1 (en) 2021-01-06
EP3759081A4 EP3759081A4 (en) 2022-01-05

Family

ID=67804887

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19760246.9A Pending EP3759081A4 (en) 2018-02-27 2019-02-18 An improved process for the preparation of propiomazine maleate

Country Status (2)

Country Link
EP (1) EP3759081A4 (en)
WO (1) WO2019167058A1 (en)

Also Published As

Publication number Publication date
WO2019167058A1 (en) 2019-09-06
EP3759081A4 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
JP5632279B2 (en) Preparation method and polymorph of ivabradine hydrochloride
KR20070084499A (en) Indoline compound and process for producing the same
CN111630049B (en) Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof
WO2014026657A2 (en) A process for the preparation of a derivative of 2-methyl-2'-phenylpropionic acid using new intermediates
KR20110036055A (en) Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
WO2012059941A1 (en) Process for preparation of sunitinib malate and salts thereof
JP2005507900A (en) Citalopram manufacturing method
US10654803B2 (en) Transition metal-catalyzed protodecarboxylation of alpha-halo-acrylic acid derivatives
KR20170102204A (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
US20090299077A1 (en) Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
TWI291956B (en) Improved process
EP1682081A2 (en) Process for manufacture of metoprolol and salts thereof
WO2012026897A1 (en) A process for the preparation of imatinib base
EP3759081A1 (en) An improved process for the preparation of propiomazine maleate
US9745264B2 (en) Method for preparing silodosin and intermediate thereof
AU2002236076B2 (en) Preparation of phthalanes
CN107428648B (en) Process for the preparation of compounds such as 3-arylbutyraldehyde useful for the synthesis of medetomidine
US7943784B2 (en) Process for the preparation of almotriptan
KR20060113792A (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
EP0489548B1 (en) A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof
US11459291B2 (en) Method of preparation of (1R,3S)-3-amino-1-cyclopentanol and salt thereof
AU2012324824B2 (en) Processes for the preparation of 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and of its precursors
CN109485567B (en) Clean preparation method of 4-hydroxymethylthiazole and intermediate thereof
FR2575469A1 (en) N-imidazolylmethyl-diphenylazomethines, a process for preparing them and their therapeutic application
GB2376945A (en) Citalopram preparation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 51/41 20060101ALI20210827BHEP

Ipc: C07D 279/28 20060101AFI20210827BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20211207

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 51/41 20060101ALI20211201BHEP

Ipc: C07D 279/28 20060101AFI20211201BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221031